Entrectinib Clinical Trials: Changing the Game with Genetic Testing

STARTRK-2 trial is a currently enrolling trial to test the efficacy and safety of the agent entrectinib which targets 5 abnormalities across a number of cancer sites. 
For Corey Wood, a 25-year-old patient with lung cancer, genetic testing was a “game changer.” Finding out that her tumor was ROS1-positive was the beginning of the path to the rest of her life.

She’s been on entrectinib, an investigational therapy that inhibits certain mutations, leading to tumor shrinkage, for almost two years now. In that time, she’s moved from California to Denver, Colorado, started working full time and is enjoying a more normal life.
"I don’t know where I would be if I wasn’t on targeted therapies,” she said, in an interview with CURE®, arranged by the Bonnie J. Addario Lung Cancer Foundation.

It was reading online forums that introduced Wood to the idea of mutations and targeted therapy — reading about this “miracle therapy.” She went to her oncologist asking about genetic testing, only to find that he had already sent her needle biopsy out to be tested. The results, however, showed that her tumor had tested negative for EGFR, ALK and KRAS, some of the more popular abnormalities.

Her oncologist didn’t give up there. He wanted to test again, and further, for more mutations. Wood said, “All I heard was, ‘You have a chance.’” It required another surgery to get a larger sample and, a few weeks later, the results were in. Wood was ROS1-positive.

“If he [her oncologist] hadn’t said, ‘Maybe we should do another test,’ I don’t think I would have pushed for it, or looked,” Wood said. For many patients, getting that testing is the first step. Pratik Multani, M.D., called it, “the entry into these potential opportunities.”

Talk about this article with other patients, caregivers, and advocates in the Lung Cancer CURE discussion group.
Special Feature
Share Your Art
Related Articles
Excitement Grows for Immunotherapy in Lung Cancer
A number of patients with lung cancer have benefitted from immunotherapy agents, and researchers in the field are excited that these treatments will continue to improve the field.
Personalized Treatment Needed for Advanced Lung Cancer
A more personalized approach is needed in treatment plans for patients with stage 3 non-small cell lung cancer (NSCLC), according to Thomas A. Hensing, M.D.
Tagrisso Approved for Frontline Lung Cancer Treatment
Tagrisso (osimertinib) was granted a Breakthrough Therapy Designation for the firstline treatment of patients who have metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC).
Related Videos
Developing a Patient-Friendly Clinical Trial Search Engine
Kathryn Burn, head of Partnerships and Research at Smart Patients, discusses her organization's role in the National Cancer Moonshot Initiative.
The Importance of Diverse Clinical Trials in Cancer
Donna Cryer, CEO and president of the Global Liver Institute, discusses the importance of having diverse clinical trials in cancer care.
Examining the Role of Stress in Lung Cancer
Syed Jafri, M.D., an assistant professor at the University of Texas McGovern School of Medicine, discusses the potential role that stress could play in lung cancer diagnoses.
//For side ad protocol